Myeloma-derived dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma

Blood

Volumn 112, Issue 1, 2008, Pages 196-207

  Qiang, Ya Wei ^a   Chen, Yu ^a   Stephens, Owen ^a   Brown, Nathan ^a   Chen, Bangzheng ^a   Epstein, Joshua ^a   Barlogie, Bart ^a   Shaughnessy Jr , John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF 1 PROTEIN; MESSENGER RNA; OLIGONUCLEOTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SHORT HAIRPIN RNA; WNT PROTEIN; WNT3 PROTEIN; DKK1 PROTEIN, HUMAN; PRIMER DNA; RECOMBINANT PROTEIN; RNA; SIGNAL PEPTIDE; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BONE ATROPHY; BONE MARROW; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; COCULTURE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; OSTEOLYSIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DNA PRIMERS; GENE EXPRESSION; GENE SILENCING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; RANK LIGAND; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSFECTION; TUMOR CELLS, CULTURED; WNT PROTEINS;

EID: 47249140444     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-132134     Document Type: Article

References (55)

1. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62-66.
2. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004;32:290-292.
3. Taube T, Beneton MN, McCloskey EV. Rogers S, Greaves M. Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992;49:192-198.
4. Anderson DM, Maraskovsky E. Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179.
5. Kong YY, Yoshida H. Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999:397:315-323.
6. Lacey DL, Timms E. Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93:165-176.
7. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
8. SudaT, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345-357.
9. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527-3533.
10. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc NatlAcad Sci U S A. 2001;98:11581-11586.
11. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064-1069.
12. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 2003; 63:287-289.
13. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002;116:278-290.
14. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, YonedaT, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001;61:2572-2578.
15. Glass DA2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-764.
16. Holmen SL, Zylstra CR, MukherjeeA, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005;280:21162-21168.
17. Jackson A, Vayssiere B, Garcia T et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone. 2005;36:585-598.
18. Galli LM, Barnes T, Cheng T, et al. Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3. Dev Dyn. 2006;235:681-690.
19. Spencer GJ, Utting JC, Etheridge SL, ArnettTR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119:1283-1296.
20. Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934-945.
21. Finch P, He X, Kelley M, et al. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci U S A. 1997;94:6770-6775.
22. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116:2627-2634.
23. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770-26775.
24. Bafico A, Liu G. Yaniv A, GazitA, Aaronson SA. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol. 2001;3:683-686.
25. Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002;417:664-667.
26. Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411:321-325.
27. Baron R, Rawadi G. Targeting the Wnt/betaoatenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-2643.
28. vanderHorst G, van der Werf SM, Farih-Sips H, van Bezooijen RL, Lowik CW. Karperien M. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J Bone Miner Res. 2005;20:1867-1877.
29. Gong Y, Slee RB. Fukai N, et al. LDL receptorrelated protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513-523.
30. Boyden LM. Mao J. Belsky J. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N EnglJ Med. 2002;346:1513-1521.
31. Little RD. Carulli JP. Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bonemass trait. Am J Hum Genet. 2002;70:11-19.
32. Tian E. Zhan F. Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494.
33. Giuliani N, Morandi F. Tagliaferri S. et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007:67:7665-7674.
34. Haaber J, Abildgaard N, Knudsen LM, et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease: only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008;140:25-35.
35. Politou MC, Heath DJ, Rahemtulla A. et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. IntJ Cancer. 2006;119:1728-1731.
36. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkkl-induced inhibition of Wnt signaling in osteoblast differentiation is the underlying mechanism of bone loss in multiple myeloma. Bone. 2008;42:669-680.
37. Yaccoby S. Ling W. Zhan F. Walker R, Barlogie B. Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106-2111.
38. Qiang Y, Kopantzev E. Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood. 2002;99:4138-4146.
39. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994;127:1755-1766.
40. Qiang Y, Endo Y, Rubin J, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene. 2003;22:1536-1545.
41. Qiang Y, Walsh K, Yao L, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005;106:1786-1793.
42. Bafico A, GazitA, Wu-Morgan SS, Yaniv A, Aaronson SA. Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene. 1998:16:2819-2825.
43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
44. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005:65:7554-7560.
45. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P. Aversatile tool for conditional gene expression and knockdown. Nat Methods. 2006; 3:109-116.
46. Qiang Y, Endo Y, Rubin J, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene. 2003;22:1536-1545.
47. Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res. 2002;8:2306-2310.
48. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with Iytic bone disease. Blood. 2001;98:2269-2271.
49. Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 2007;67:202-208.
50. Fujita KI, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer. 2007;6:71.
51. Gregory CA, Singh H, Perry AS, Prockop DJ. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem. 2003;278:28067-28078.
52. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006;24:986-991.
53. Kishimoto T. Interleukin-6: from basic science to medicine: 40 years in immunology. Annu Rev Immunol. 2005;23:1-21.
54. Fulciniti M, Tassone P, HideshimaT, et al. Antidkk1 mAb (BHO880) as a potential therapeutic for multiple myeloma[abstract]. Blood. 2007;110:169a. Abstract 551.
55. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156-163.